United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, …

Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...

Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)

Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...

Prebys Ventures invests $5 million in five San Diego healthcare startups

Prebys Ventures announced it has invested $5 million into five San Diego startup companies working on the cutting edge of ...
Hometown Station

Providence Holy Cross Medical Center Offers Innovative COPD And Emphysema Treatment

Providence Holy Cross Medical Center is the first Providence hospital in the San Fernando Valley to offer a minimally ...

Molecular switch discovery may unlock regenerative therapies for lung disease

Mayo Clinic researchers have identified a molecular "switch" in lung cells that helps them decide when to repair tissue and ...
Ahram Online

The Egyptian Drug Authority approves the launch of “Trelegy Ellipta” — a new hope for patients with chronic obstructive pulmonary disease (COPD) and asthma.

The global pharmaceutical company GSK announced the launch of “Trelegy Ellipta” following the approval of the Egyptian Drug Authority. Trelegy represents a new breakthrough in the treatment of chronic ...